Loading…

Treatment patterns and economic burden among cervical and endometrial cancer patients newly initiating systemic therapy

To evaluate treatment patterns, healthcare resource use (HCRU) and all-cause healthcare costs among patients with cervical or endometrial cancer newly initiating systemic therapy. We identified patients with cervical or endometrial cancer newly initiating systemic therapy – a claims-based proxy for...

Full description

Saved in:

Bibliographic Details
Published in:	Future oncology (London, England) England), 2022-03, Vol.18 (8), p.953-964
Main Authors:	Kebede, Nehemiah, Shah, Ruchit, Shah, Anuj, Corman, Shelby, Nwankwo, Chizoba
Format:	Article
Language:	English
Subjects:	advanced cancer Aged Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use cervical cancer endometrial cancer Endometrial Neoplasms - drug therapy Endometrial Neoplasms - economics Female Health Care Costs Health Services Accessibility healthcare costs Humans Insurance Claim Review Middle Aged Retrospective Studies systemic therapies treatment patterns United States Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - economics
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c382t-d17da5db92f39c34ed8ae9314a7a25b6f8646d6dc9619e9962a3440123f7d6173
cites	cdi_FETCH-LOGICAL-c382t-d17da5db92f39c34ed8ae9314a7a25b6f8646d6dc9619e9962a3440123f7d6173
container_end_page	964
container_issue	8
container_start_page	953
container_title	Future oncology (London, England)
container_volume	18
creator	Kebede, Nehemiah Shah, Ruchit Shah, Anuj Corman, Shelby Nwankwo, Chizoba
description	To evaluate treatment patterns, healthcare resource use (HCRU) and all-cause healthcare costs among patients with cervical or endometrial cancer newly initiating systemic therapy. We identified patients with cervical or endometrial cancer newly initiating systemic therapy – a claims-based proxy for advanced disease – between 2014 and 2019, described them by line of therapy (LOT), and summarized the per patient per month (PPPM) HCRU and healthcare costs per LOT. Among 1229 patients with cervical cancer and 2659 patients with endometrial cancer, LOT1 therapies included systemic only (cervical, 50.1%; endometrial, 83.2%) and systemic with radiation therapy (cervical, 49.9%; endometrial, 16.8%). Mean PPPM total costs were: LOT1 (cervical, US$15,892; endometrial, US$11,363), LOT2 (US$20,193; US$14,019) and LOT3+ (US$16,576; US$14,645). Overall, patients received guideline-concordant care and experienced significant economic burden, which increased with LOT.
doi_str_mv	10.2217/fon-2021-0772
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2624198983</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2624198983</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-d17da5db92f39c34ed8ae9314a7a25b6f8646d6dc9619e9962a3440123f7d6173</originalsourceid><addsrcrecordid>eNp1kDlPwzAYQC0EolwjK8rIEvBVOx5RxSVVYoHZcu0vYJQ4xXZA_fc4CrCx-HzfGx5C5wRfUUrkdTuEmmJKaiwl3UNHRHJeNwyT_XLmUtVCKL5Axym9Y8wlW-JDtCir4kshjtDXcwSTewi52pqcIYZUmeAqsEMYem-rzRgdhMr0Q3itLMRPb003I8ENPeToy92aUP4mhS-qVAX46naVDz778lQm0y5lmHz5DaLZ7k7RQWu6BGc_-wl6ubt9Xj3U66f7x9XNurasobl2RDqzdBtFW6Ys4-AaA4oRbqShy41oG8GFE84qQRQoJahhnGNCWSudIJKdoMvZu43Dxwgp694nC11nAgxj0lRQTlSjGlbQekZtHFKK0Opt9L2JO02wnlrr0lpPrfXUuvAXP-px04P7o3_jFkDNQDvmMUKypY0FPd_KhLc-wD_yb8QwkHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624198983</pqid></control><display><type>article</type><title>Treatment patterns and economic burden among cervical and endometrial cancer patients newly initiating systemic therapy</title><source>Open Access: PubMed Central</source><creator>Kebede, Nehemiah ; Shah, Ruchit ; Shah, Anuj ; Corman, Shelby ; Nwankwo, Chizoba</creator><creatorcontrib>Kebede, Nehemiah ; Shah, Ruchit ; Shah, Anuj ; Corman, Shelby ; Nwankwo, Chizoba</creatorcontrib><description>To evaluate treatment patterns, healthcare resource use (HCRU) and all-cause healthcare costs among patients with cervical or endometrial cancer newly initiating systemic therapy. We identified patients with cervical or endometrial cancer newly initiating systemic therapy – a claims-based proxy for advanced disease – between 2014 and 2019, described them by line of therapy (LOT), and summarized the per patient per month (PPPM) HCRU and healthcare costs per LOT. Among 1229 patients with cervical cancer and 2659 patients with endometrial cancer, LOT1 therapies included systemic only (cervical, 50.1%; endometrial, 83.2%) and systemic with radiation therapy (cervical, 49.9%; endometrial, 16.8%). Mean PPPM total costs were: LOT1 (cervical, US$15,892; endometrial, US$11,363), LOT2 (US$20,193; US$14,019) and LOT3+ (US$16,576; US$14,645). Overall, patients received guideline-concordant care and experienced significant economic burden, which increased with LOT.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2021-0772</identifier><identifier>PMID: 35094566</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>advanced cancer ; Aged ; Antineoplastic Agents - economics ; Antineoplastic Agents - therapeutic use ; cervical cancer ; endometrial cancer ; Endometrial Neoplasms - drug therapy ; Endometrial Neoplasms - economics ; Female ; Health Care Costs ; Health Services Accessibility ; healthcare costs ; Humans ; Insurance Claim Review ; Middle Aged ; Retrospective Studies ; systemic therapies ; treatment patterns ; United States ; Uterine Cervical Neoplasms - drug therapy ; Uterine Cervical Neoplasms - economics</subject><ispartof>Future oncology (London, England), 2022-03, Vol.18 (8), p.953-964</ispartof><rights>2022 Merck & Co., Inc., and its affiliates</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-d17da5db92f39c34ed8ae9314a7a25b6f8646d6dc9619e9962a3440123f7d6173</citedby><cites>FETCH-LOGICAL-c382t-d17da5db92f39c34ed8ae9314a7a25b6f8646d6dc9619e9962a3440123f7d6173</cites><orcidid>0000-0002-3553-6142</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35094566$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kebede, Nehemiah</creatorcontrib><creatorcontrib>Shah, Ruchit</creatorcontrib><creatorcontrib>Shah, Anuj</creatorcontrib><creatorcontrib>Corman, Shelby</creatorcontrib><creatorcontrib>Nwankwo, Chizoba</creatorcontrib><title>Treatment patterns and economic burden among cervical and endometrial cancer patients newly initiating systemic therapy</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>To evaluate treatment patterns, healthcare resource use (HCRU) and all-cause healthcare costs among patients with cervical or endometrial cancer newly initiating systemic therapy. We identified patients with cervical or endometrial cancer newly initiating systemic therapy – a claims-based proxy for advanced disease – between 2014 and 2019, described them by line of therapy (LOT), and summarized the per patient per month (PPPM) HCRU and healthcare costs per LOT. Among 1229 patients with cervical cancer and 2659 patients with endometrial cancer, LOT1 therapies included systemic only (cervical, 50.1%; endometrial, 83.2%) and systemic with radiation therapy (cervical, 49.9%; endometrial, 16.8%). Mean PPPM total costs were: LOT1 (cervical, US$15,892; endometrial, US$11,363), LOT2 (US$20,193; US$14,019) and LOT3+ (US$16,576; US$14,645). Overall, patients received guideline-concordant care and experienced significant economic burden, which increased with LOT.</description><subject>advanced cancer</subject><subject>Aged</subject><subject>Antineoplastic Agents - economics</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>cervical cancer</subject><subject>endometrial cancer</subject><subject>Endometrial Neoplasms - drug therapy</subject><subject>Endometrial Neoplasms - economics</subject><subject>Female</subject><subject>Health Care Costs</subject><subject>Health Services Accessibility</subject><subject>healthcare costs</subject><subject>Humans</subject><subject>Insurance Claim Review</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>systemic therapies</subject><subject>treatment patterns</subject><subject>United States</subject><subject>Uterine Cervical Neoplasms - drug therapy</subject><subject>Uterine Cervical Neoplasms - economics</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kDlPwzAYQC0EolwjK8rIEvBVOx5RxSVVYoHZcu0vYJQ4xXZA_fc4CrCx-HzfGx5C5wRfUUrkdTuEmmJKaiwl3UNHRHJeNwyT_XLmUtVCKL5Axym9Y8wlW-JDtCir4kshjtDXcwSTewi52pqcIYZUmeAqsEMYem-rzRgdhMr0Q3itLMRPb003I8ENPeToy92aUP4mhS-qVAX46naVDz778lQm0y5lmHz5DaLZ7k7RQWu6BGc_-wl6ubt9Xj3U66f7x9XNurasobl2RDqzdBtFW6Ys4-AaA4oRbqShy41oG8GFE84qQRQoJahhnGNCWSudIJKdoMvZu43Dxwgp694nC11nAgxj0lRQTlSjGlbQekZtHFKK0Opt9L2JO02wnlrr0lpPrfXUuvAXP-px04P7o3_jFkDNQDvmMUKypY0FPd_KhLc-wD_yb8QwkHw</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Kebede, Nehemiah</creator><creator>Shah, Ruchit</creator><creator>Shah, Anuj</creator><creator>Corman, Shelby</creator><creator>Nwankwo, Chizoba</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3553-6142</orcidid></search><sort><creationdate>20220301</creationdate><title>Treatment patterns and economic burden among cervical and endometrial cancer patients newly initiating systemic therapy</title><author>Kebede, Nehemiah ; Shah, Ruchit ; Shah, Anuj ; Corman, Shelby ; Nwankwo, Chizoba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-d17da5db92f39c34ed8ae9314a7a25b6f8646d6dc9619e9962a3440123f7d6173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>advanced cancer</topic><topic>Aged</topic><topic>Antineoplastic Agents - economics</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>cervical cancer</topic><topic>endometrial cancer</topic><topic>Endometrial Neoplasms - drug therapy</topic><topic>Endometrial Neoplasms - economics</topic><topic>Female</topic><topic>Health Care Costs</topic><topic>Health Services Accessibility</topic><topic>healthcare costs</topic><topic>Humans</topic><topic>Insurance Claim Review</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>systemic therapies</topic><topic>treatment patterns</topic><topic>United States</topic><topic>Uterine Cervical Neoplasms - drug therapy</topic><topic>Uterine Cervical Neoplasms - economics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kebede, Nehemiah</creatorcontrib><creatorcontrib>Shah, Ruchit</creatorcontrib><creatorcontrib>Shah, Anuj</creatorcontrib><creatorcontrib>Corman, Shelby</creatorcontrib><creatorcontrib>Nwankwo, Chizoba</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kebede, Nehemiah</au><au>Shah, Ruchit</au><au>Shah, Anuj</au><au>Corman, Shelby</au><au>Nwankwo, Chizoba</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment patterns and economic burden among cervical and endometrial cancer patients newly initiating systemic therapy</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>18</volume><issue>8</issue><spage>953</spage><epage>964</epage><pages>953-964</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>To evaluate treatment patterns, healthcare resource use (HCRU) and all-cause healthcare costs among patients with cervical or endometrial cancer newly initiating systemic therapy. We identified patients with cervical or endometrial cancer newly initiating systemic therapy – a claims-based proxy for advanced disease – between 2014 and 2019, described them by line of therapy (LOT), and summarized the per patient per month (PPPM) HCRU and healthcare costs per LOT. Among 1229 patients with cervical cancer and 2659 patients with endometrial cancer, LOT1 therapies included systemic only (cervical, 50.1%; endometrial, 83.2%) and systemic with radiation therapy (cervical, 49.9%; endometrial, 16.8%). Mean PPPM total costs were: LOT1 (cervical, US$15,892; endometrial, US$11,363), LOT2 (US$20,193; US$14,019) and LOT3+ (US$16,576; US$14,645). Overall, patients received guideline-concordant care and experienced significant economic burden, which increased with LOT.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>35094566</pmid><doi>10.2217/fon-2021-0772</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-3553-6142</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1479-6694
ispartof	Future oncology (London, England), 2022-03, Vol.18 (8), p.953-964
issn	1479-6694 1744-8301
language	eng
recordid	cdi_proquest_miscellaneous_2624198983
source	Open Access: PubMed Central
subjects	advanced cancer Aged Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use cervical cancer endometrial cancer Endometrial Neoplasms - drug therapy Endometrial Neoplasms - economics Female Health Care Costs Health Services Accessibility healthcare costs Humans Insurance Claim Review Middle Aged Retrospective Studies systemic therapies treatment patterns United States Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - economics
title	Treatment patterns and economic burden among cervical and endometrial cancer patients newly initiating systemic therapy
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A25%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20patterns%20and%20economic%20burden%20among%20cervical%20and%20endometrial%20cancer%20patients%20newly%20initiating%20systemic%20therapy&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Kebede,%20Nehemiah&rft.date=2022-03-01&rft.volume=18&rft.issue=8&rft.spage=953&rft.epage=964&rft.pages=953-964&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2021-0772&rft_dat=%3Cproquest_cross%3E2624198983%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c382t-d17da5db92f39c34ed8ae9314a7a25b6f8646d6dc9619e9962a3440123f7d6173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2624198983&rft_id=info:pmid/35094566&rfr_iscdi=true